Inodiftagene vixteplasmid - Anchiano Therapeutics

Drug Profile

Inodiftagene vixteplasmid - Anchiano Therapeutics

Alternative Names: BC-819; BC-819/PEI; Diphtheria-toxin-A-H19; DTA-H19; DTA-H19/PEI

Latest Information Update: 30 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioCancell Therapeutics
  • Developer Anchiano Therapeutics
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer
  • No development reported Liver cancer; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 25 Oct 2018 BioCancell Therapeutics plans two registrational trials for Bladder cancer, one of the trials, the phase II Codex, is anticipated to initiate in November 2019 (NCT03719300)
  • 27 Aug 2018 BioCanCell Therapeutics is now called Anchiano Therapeutics
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top